Evicenter
P&T meetings

4D-150

Neovascular age-related macular degeneration

Regulatory submission
Not announced
Launch
Not announced
Last updated
180 sources

Product information and disease descriptionProduct descriptionProduct information

Special populations

3 evidence topics · 1 source

Age eligibility in the Phase 3 trials

“≥50 years of age at time of consent” (opens the source at this quote in a new tab)

“Ages Eligible for Study 50 Years and older (Adult, Older Adult )” (opens the source at this quote in a new tab)

Ocular comorbidity exclusions

“History of retinal detachment in the study eye” (opens the source at this quote in a new tab)

“History of or presence of active inflammation in either eye” (opens the source at this quote in a new tab)

“Glaucoma or intraocular hypertension requiring more than 2 topical medications for control” (opens the source at this quote in a new tab)

Systemic condition exclusions relevant to immune and cardiovascular risk

“Acute coronary syndrome, myocardial infarction or coronary artery revascularization, cerebrovascular accident, transient ischemic attack within 6 months of the Screening Visit” (opens the source at this quote in a new tab)

“History of autoimmune condition that may predispose to the development of uveitis” (opens the source at this quote in a new tab)

Pediatric use, pregnancy and lactation, renal and hepatic impairment, and use in participants with pre-existing antibodies to the capsid

No evidence found.